News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Scores highest PAT of Rs. 118 crore in FY25
This marks yet another milestone in our series of successful audits over the past year
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Findings likely to generate hypotheses about potential new uses of drugs
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
AstraZeneca Pharma India discontinues manufacturing of Imdur
Positions Curium as leading manufacturer of Lu-177 isotope
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Subscribe To Our Newsletter & Stay Updated
